ArticleClinical and experimental hepatology2024
Prevalence of HDV infections in Poland based on the experience of a single center in Silesia and literature research.
Article in Clinical and experimental hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recommendations for treatment of viral hepatitis B in 2026 by the Polish Group of Experts for HBV.Clinical and experimental hepatology · 2026Review
- Towards elimination of viral hepatitis in the Czech Republic, Hungary, Poland and Slovakia: insights from the Viral Hepatitis Prevention Board (VHPB).Clinical and experimental hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: Hepatitis delta virus (HDV) causes the most aggressive and rapidly progressive form of viral hepatitis. However, detailed data about epidemiology and risk factors in Polish population are still lacking. Thus, the aim of this retrospective study was to determine the prevalence of HDV infection among a Silesian population of patients infected with HBV. Material and methods: 177 patients with confirmed hepatitis B virus (HBV) infection were examined for HDV infection. The diagnostic methods used in this study were measurement of HDV antibodies and HDV antigen levels. A telephone follow-up of patients who tested positive indicating HDV infection was conducted, in which they were asked about their current health status, the course of HDV infection and possible risk factors. Results: The prevalence of HDV infection was 3.4%. Four of six patients already had an advanced level of liver fibrosis (F3 or higher) before starting treatment, one of them having undergone liver transplantation. Alanine aminotransferase (ALT) levels in HDV patients were above normal in half of the cases. Except for two cases, no risk factors were identified that may favor HDV infection. Conclusions: Hepatitis D is a serious disease that requires more attention. Due to the limitations of our study, larger-scale studies answering the question of the prevalence of HDV in Poland are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.